Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Other Non-Current Assets (2016 - 2025)

Vistagen Therapeutics' Other Non-Current Assets history spans 12 years, with the latest figure at $392000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 17.82% year-over-year to $392000.0; the TTM value through Dec 2025 reached $392000.0, down 17.82%, while the annual FY2025 figure was $454000.0, 37.47% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $392000.0 at Vistagen Therapeutics, down from $405000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $726000.0 in Q1 2024 and bottomed at $47800.0 in Q1 2021.
  • The 4-year median for Other Non-Current Assets is $392000.0 (2025), against an average of $324033.3.
  • The largest annual shift saw Other Non-Current Assets crashed 54.31% in 2021 before it skyrocketed 413.38% in 2024.
  • A 4-year view of Other Non-Current Assets shows it stood at $133500.0 in 2021, then fell by 24.42% to $100900.0 in 2023, then surged by 372.75% to $477000.0 in 2024, then fell by 17.82% to $392000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Other Non-Current Assets are $392000.0 (Q4 2025), $405000.0 (Q3 2025), and $472000.0 (Q2 2025).